title: Myeloma in scar tissue--an underreported phenomenon or an emerging entity in the novel agents' era? A single center series.
abstract: Tumor relapse in scar tissue is uncommon in cancer patients. Likewise, extramedullary plasmacytoma (EMP) relapse in scar tissue in the setting of multiple myeloma (MM) has been rarely reported. We report a series of 3 patients whose disease progressed as EMP at the site of a wound from previous invasive procedures. All 3 patients were treated for the relapsed disease with different treatment modalities, but failed to respond adequately and died several months after relapse. At original MM diagnosis, all had advanced-stage disease. They were treated with novel agents with or without autologous hematopoietic stem cell transplantation and achieved either a complete or very good partial response. We suggest that these treatments, which have become the standard of care in MM, may permit a predominance of myeloma subclones which are independent of the bone marrow microenvironment. These myeloma subclones then gain a survival advantage in the active scar-tissue niche, allowing for their uncontrolled proliferation. This case series might represent an underreported phenomenon and therefore may indicate an emerging and difficult-to-treat disease in the era of targeted therapies in MM. Physicians treating MM should be aware of this phenomenon, especially when referring their patients for invasive procedures.
authors.affiliation: Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.
authors.forename: Eli
authors.initials: E
authors.lastname: Muchtar
authors.forename: Pia
authors.initials: P
authors.lastname: Raanani
authors.forename: Moshe
authors.initials: M
authors.lastname: Yeshurun
authors.forename: Ofer
authors.initials: O
authors.lastname: Shpilberg
authors.forename: Hila
authors.initials: H
authors.lastname: Magen-Nativ
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002921:Cicatrix / Q000150:complications* / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000473:pathology / Q000628:therapy; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D010954:Plasmacytoma / Q000150:complications / Q000473:pathology / Q000628:therapy